Form 4: Director Jack Wyszomierski Sells Exelixis Shares

Exelixis, Inc. Director Jack Wyszomierski sold 3,925 shares of common stock pursuant to a pre-established Rule 10b5-1 trading plan.

Summary

• Director Jack Wyszomierski sold 3,925 shares of Exelixis, Inc. (EXEL) common stock.
• The transaction occurred on June 1, 2026, at a price of $50.55 per share.
• The sale was executed under a Rule 10b5-1 trading plan adopted on November 19, 2025.
• Following the transaction, the director retains beneficial ownership of 284,384 shares, including 8,367 shares underlying restricted stock units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed under a pre-existing, automated trading plan.

Positives

• The sale was conducted via a pre-planned Rule 10b5-1 trading plan, which is a standard mechanism for insiders to sell shares without triggering concerns regarding non-public information.

Negatives

• The transaction represents a reduction in the director's direct equity stake in the company.

Risks

• Insider selling can sometimes be perceived negatively by the market, though this specific transaction was pre-planned.

Future Outlook

No forward-looking guidance or operational outlook was provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling via 10b5-1 plans is common in the biotechnology sector and generally does not signal a change in corporate strategy or outlook.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate insiders to manage equity holdings while maintaining regulatory compliance.

Stakeholder Impact

• Minimal impact on shareholders as the sale was pre-planned and represents a small fraction of the director's total holdings.

Key Dates

Keywords

Exelixis, EXEL, Insider Trading, Form 4, Biotech, Director Sale